ASHP CLINICAL SKILLS COMPETITION PHARMACIST'S PATIENT DATA BASE FORM

Demographic and Administrative Information				
Name: AJ	Patient ID: 525652	5		
Address: 101 Doctor Perry Road	Room & Bed: Out	patient Fam	ily Medicine	Clinic
Harpers Ferry, WV	Physician: Johnson	<u> </u>		
Date of Birth: 4/12/1950	Pharmacy: Save a	Lot Pharma	cy	
Height: 5'10"	Race: Caucasian			
Weight: 99 kg				
Gender: Male				
History of Present Illness	Vitals & Other Te	ests		
Patient presents to the family medicine clinic for a recheck on his		10/1/07	0/19/09	2/15/07
blood pressure and a general health maintenance visit. Patient was in to see his doctor 2 weeks ago, at which time his BP was 168/98		10/1/07 (today)	9/17/07	3/15/07
mmHg. His blood pressure medications were adjusted by his	BP mmHg	156/94	168/98	150/90
physician (see current drug therapy) and he was asked to come back	HR	52	70	72
in two weeks for a BP recheck. His only complaint is that he feels	Temp F	98.8	97.5	98.2
very fatigued since his visit two weeks ago.	Resp	16	16	14
	Weight	99 kg	96 kg	94 kg
	Arthritis Pain	2/10	2/10	2/10
Past Medical History	Chem (ALL FAS	TING)		
Hypertension (2001)			1 - 1 - 1	
Dyslipidemia (2002)		9/17/07	3/15/07	9/20/06
Osteoarthritis – hip and knee (2000)	Na mEq/L	135	139	136
GERD (1998)	K mEq/L	4.2	3.9	4.1
Obesity	Cl mEq/L	105	99	110
	CO2 mEq/L	25	23	27
	Gluc mg/dL	122	120	118
	BUN mg/dL	20	18	19
	SCr mg/dL	0.9	0.7	0.7
	Calcium mg/dL	9.2	9.8	9.0
	Albumin g/dL	4.0	4.2	4.2
	AST units/L	36	38	32
	ALT units/L	35	36	40
	Total Bili	1.1	1.2	0.8
	mg/dL Dir Bili mg/dL	0.1	0.2	0.0
	Dir Bill mg/dr	0.1	0.2	0.0
Family History				
Father: deceased; stroke at age 65				
Mother: alive (age 78); type 2 diabetes; hypertension				
Sister: alive (age 55); prehypertension				
Brother: alive (53); well				

Social History	Fasting Lipids
Tobacco: 1 pack per day for 30 years ETOH: patient states that he stopped drinking alcohol when he stopped using drugs Illicit Drugs: "I used to smoke weed 20 years ago, but not anymore" Caffeine: 3 cans of regular soda daily Occupation: self-employed painter Status: divorced Children: none Physical Activity: only that activity he gets on the job (e.g. walking; climbing ladders to paint) Diet: whatever is "cheap"; usually a burger and fries from McDonalds Vaccinations: last tetanus shot at age 23	Pasting Lipids 9/17/07 3/15/07 9/20/06 TC mg/dL 205 190 195 LDL mg/dL 140 135 130 Trigs mg/dL 142 145 140 HDL mg/dL 30 32 37

Physical Exam (10-1-07) - today

General statement: Obese white male who is alert, oriented and cooperative.

VITALS: BP 156/94; HR 52; T 98.8; RR 16

SKIN: Normal in appearance, texture, and temperature

<u>HEENT</u>: Pupils equally round, 4 mm, reactive to light and accommodation, sclera and conjunctivae normal. Funduscopic examination reveals arteriolar narrowing and AV nicking. Tympanic membranes and external auditory canals normal. Nasal mucosa normal. Oral pharynx is normal without erythema or exudate.

LUNGS: clear bilaterally with no wheezing, no ronchi, no rales

<u>CARDIOVASCULAR</u>: Regular rate and rhythm (RRR). Normal carotid pulsations without bruits. S1 and S2 normal with physiologic S2 split. No S3 or S4. 2/6 soft crescendo-decrescendo systolic murmur best heard over the left 3rd interspace.

ABDOMEN: Obese, nontender, nondistended; no abdominal bruits appreciated

GENITOURINARY: patient deferred

RECTAL: patient deferred

EXTREMITIES: No cyanosis, clubbing, or edema are noted. Peripheral pulses in the femoral, popliteal, anterior tibial, dorsalis pedis, brachial, and radial areas are 2+. Patient has a reduced range of motion in his hip.

<u>NEUROLOGICAL</u>: cranial nerves II – XII intact, deep tendon reflexes normal; No complaints of weakness, numbness, or incoordination.

ASHP CLINICAL SKILLS COMPETITION PHARMACIST'S PATIENT DATA BASE FORM (Cont.)

Allergies/Intolerance's Prescription Coverage				
Penicillin (rash)		Insurance: Blue Cross		
Codeine (stomach upset per patient)		Copay: \$15 (generic); \$30 (brand tier 1); \$40 (brand tier 2); \$50 (brand tier 3)		
		Cost per month: \$120-130 per n	nonth if all meds are purchased	
		Annual Income: Approximately	\$25,000 per year	
Current Drug Therapy				
Drug Name/Dose/Strength/Route	Prescribed Schedule	Duration Start-Stop Dates	Compliance/Dosing Issue	
1. metoprolol 25 mg	1 PO twice daily	5/07/03 — 9/17/07		
2. metoprolol 50 mg	1 PO twice daily	9/17/07 – present		
3. HCTZ 25 mg	1 PO daily	10/05/01 - present		
4. atorvastatin 10 mg	1 PO daily	5/20/02 - present	Patient has not purchased or taken for past three months due to high price co-pay (\$50/month)	
5. esomeprazole 40 mg	1 PO daily	1998 – present	Patient purchases this PRN when he can afford it (\$50/month)	
6. acetaminophen 500 mg	2 PO three times daily	2001 - present		
7.				
8.				
9.				
10.				
11.				
12.				
13.				
14.			-	
15. 16.				
17.				
Medication History				

Metoprolol was increased from 25 mg bid to 50 mg bid at patient's visit 2 weeks ago (on 9/17/07) when his BP was 168/98. He has taken both esomeprazole and atorvastatin at the stated dose since initiation, although the patient states that some months, he cannot afford to buy them due to his high co-pay amounts. Prior to the dosing schedule listed above, the patient used acetaminophen PRN for his arthritis pain. He was advised to begin this above listed dosing schedule when he consistently was having pain rated 6 out of 10.

ASHP Clinical Skills Competition - Pharmacist's Care Plan

Evaluated for competition

T	eam	#	

Problem Identification and Prioritization with Pharmacist's Care Plan

- A. List all health care problems that need to be addressed in this patient using the table below.
- B. Prioritize the problems by indicating the appropriate number in the "Priority" column below:
 - 1 = Most urgent problem (Note: There can only be one most urgent problem)
 - 2 = Other problems that must be addressed immediately or during this clinical encounter; **OR**
 - 3 = Problems that can be addressed later (e.g. a week or more later)
- *Please note, there should be only a "1", "2", or "3" listed in the priority column, and the number "1" should only be used once.

Health Care Problem	Priority	Therapeutic Goals	Recommendations for Therapy	Monitoring Parameters and Endpoints
Hypertension	1	BP <130/80 Reduction in CV and renal morbidity and mortality	 Continue HCTZ AND Decrease metoprolol back to 25 mg twice daily (b/c HR is 52) OR taper it until discontinued completely AND Institute diet and exercise modifications per JNC7 guidelines (see below) 	 BP<140/90 (JNC7) q2-4wks BP<130/80 q2-4wks (AHA - 1 bonus point if students know new AHA goal) HR 60-100 q2-4wks K 3.5-5.5 q 3 months SCr 0.6-1.2 q 3months Cough (if ACEI is chosen for drug therapy) Fatigue/SOB if beta- blocker is continued

Health Care Priority . Therapeutic	Recommendations for Therapy	Monitoring Parameters and
Problem Goals .		Endpoints
	Table's Lifestyle modifications to manage hypertension	
		PROVINCIO SBE
	DODIFICATION RECOMMENDATION RE	SUCTION (RANGE)
		commHg/10 kg
		ι4 mmHg ⁻³⁻⁴
	vegetables, and lowfat dairy products with a reduced content	
	of saturated and total fat.	
	Dietary sodium reduction Reduce dietary sodium intake to 2-	3.mmHg ^{3t-47}
	no more than 100 mmol per day	
	(2.4 g sodium or 6 g sodium chloride).	
		o mmHg ^{athop}
	activity such as brisk walking (at least 30 min per day, most	
	days of the week).	
	Moderation of alcohol Limit consumption to no more than 2-	4 mmHg**
	consumption 2 drinks (1 oz or 30 mL ethanol;	
	or 3 oz 80-proof whiskey)	
	per day in most men and to no more than 1 drink per day in women	
	and lighter weight persons.	
	DASH, Dietary Approaches to Stop Hypertension.	
	 For overall cardiovascular risk reduction, stop smolding. The effects of implementing these modifications are dose and time dependent, and could 	be greater for some
	Individuals.	
	AND any ONE drug from EITHER the ACEL	r CCB list
	Add a generic ACE Inhibitor and titrate to BP goal	
	o benazepril 10-40 mg/day	
	o captopril 25-100 mg/day	
	o enalapril 5-40 mg/day	
	o fosinopril 10-40 mg/day	
	o lisinorpil 10-40 mg/day	
	o moexipril 7.5-30 mg/day	
	o quinapril 10-80 mg/day	
	o trandolapril 1-4 mg/day	
	Add a generic CCB and titrate to BP goal	
	o amilodipine 2.5-10 mg/day	
	o felodipine 2.5-20 mg/day	
	o isradipine 2.5-10 mg/day	
	o nicardipine SR 60-120 mg/day	
	o nifedipine LA 30-60 mg/day	
2 2007 4 CHI AND COMPANY TO ALL SIGN		

Health Care Priority Therapeutic Goals Recommendatio	
Health Care Priority Therapeutic Goals Recommendatio	
Problem	ns for Therapy Monitoring Parameters and Endpoints
Prevent coronary events and stroke LDL <100 (based on Framingham) [30% reduction from 140 where he is now] Trigs <150 HDL >40 • CHD risk • Prevent coronary events and stroke • LDL <100 (based on Framingham) [30% reduction from 140 where he is now] • Trigs <150 HDL >40 • TC <200	lipid panel q6-12 wks lay • ALT/AST/Tbili q6-12 wks odifications per ATP III saturated fats (McDonalds), ↑ lipid panel q6-12 wks • MLT/AST/Tbili q6-12 wks

Health Care Priority Problem	Therapeutic Goals	Recommendations for Therapy	Monitoring Parameters and Endpoints
Tobacco Use 2	 Stop smoking Improve cardiovascula r health Prevent MI 	 Smoking cessation counseling Nonpharmacologic therapy Stages of change to assess willingness to quit Precontemplation Contemplation Preparation Action Maintenance Brief physician/practitioner advice Telephone counseling Self help materials Pharmacologic therapy (choose one or dual therapy if bupropion is one of agents selected) Bupropion SR 150 mg q morning for 3 days then 150 bid (duration: 7-12 weeks maintenance up to 6 months) Nicotine Gum 2-4 mg (up to 24 pieces/day) (duration: up to 12 weeks) Nicotine inhaler 6-16 cartridges/day (duration up to 6 months) Nicotine nasal spray 8-40 doses/day (duration: 3-6 months) Nicotine patch step down therapy – 21 mg/day for 4 weeks, then 14mg/day for 2 weeks then 7 mg/day for 2 weeks Varenicline (Chantix) 0.5 mg daily x 3 days, then 0.5 mg twice daily days 4-7, then 1 mg twice daily for weeks 2-12 	 Smoking cessation Decrease in # of number of cigarettes per day until cessation is achieved AE of drugs Bupropion (tachycardia, HA, insomnia, dizziness) Nicotine spray/inhaler (HA, mouth/throat irritation, cough, rhinitis) Nicotine patch (application site reaction, rash) Varenicline (nausea, sleep disturbances)

Health Care Problem	Priority	Therapeutic Goals	Recom	mendations for Therapy	Monitoring Parameters, and Endpoints
自己的性格性性的反射性。其中可以使用性质的成果的不同的性性的发展。其他的一种性性的原则性的一种性性的原则性的一种性性的一种性性的一种性性的一种性性的一种性性的一种性性的一种性性的一种	2	Reduce cardio- vascular morbidity and mortality Weight loss (lose at least 10% of patients total body weight) Improve patients current disease states (HTN, Dys- lipidemia, elevated blood glucose) Prevent/delay	DIET Low-Calorie Step Diet Nutrient Calories¹ Total fat² Saturated fatty acids³ Monounsaturated fatty acids Polyunsaturated fatty acids Cholesterol³ Protein⁴ Carbohydrate⁵ Sodium Chloride Calcium6 Fiber⁵ PHYSICAL ACTIVIT O Increased phy O Goal of 30 mi	Recommended Intake Approximately 500 to 1,000 kcal/day reduction from usual intake 30 percent or less of total calories 8 to 10 percent of total calories Up to 15 percent of total calories Up to 10 percent of total calories 	

Health Care Problem	Priority	Therapeutic Goals	Recommendations for Therapy	Monitoring Parameters and Endpoints
Arthritis	2	 Control pain associated with osteoarthritis Maintain mobility and functionality of hip/knee Weight loss (1 bonus point if student states loss of at least 10% of current body weight) Maintained QOL and ability to perform ADL's 	Continue APAP 1000mg three times daily Recommend physical therapy for improved mobility and function	 LFT's in normal range Pain continued at 2/10 or lower Maintained QOL and ability to perform ADL's

Health Care Problem	Priority	Therapeutic Goals	Recommendations for Therapy	Monitoring Parameters and Endpoints
Vaccinations	3	 Prevent influenza virus infection Prevent hospital admission and illness 	 Influenza vaccine yearly Patient currently due for tetanus vaccine (1 bonus point if student lists Adacel or Tdap) 	 Symptoms of respiratory illness (e.g., fever, chills, cough dyspnea) Adverse reaction from injection (e.g., pain, swelling)
GERD	3	 Prevent mucosal damage in the esophagus Prevent complication s associated with GERD (e.g. Barrett's esophagus) 	 D/C esomeprazole (Nexium) 40 mg QDay and initiate a lower cost generic PPI omeprazole 20-40 mg/day OR if patient's symptoms are relatively well controlled, a low cost H2 blocker (such as ranitidine or famotidine, which can both be purchased for \$4/month via low cost generic drug program) could also be initiated on a trial basis. famotidine 20 mg twice daily ranitidine 150-300 mg/day nizatidine 150 mg twice daily AND Institute lifestyle modifications to treat GERD, including elevation of the head of the bed, ↓ fat intake, cessation of smoking, and avoiding recumbency for 3 hours PP 	 Frequency of GERD symptoms (e.g. heartburn and regurgitation) \$\psi\$/alleviate GERD symptoms

Health Care Problem	Priority.	Therapeutic Goals	Recommendations for Therapy	Monitoring Parameters and Endpoints
Health Maintenance (Colonoscopy, Prostate)	3	Identify early cancers	 Baseline colon screening >50 years (see examples below. One bonus point if the student lists one of the colon screening options below) 	Test results per physician
			American Cancer Society Colorectal Cancer Screening Guidelines	
			Beginning at age 50, men and women who are at average risk for developing colorectal cancer should have 1 of the 5 screening options below:	
			 a fecal occult blood test (FOBT)* or fecal immunochemical test (FIT)* every year**, OR flexible sigmoidoscopy every 5 years, OR an FOBT* or FIT* every year plus flexible sigmoidoscopy every 5 years**, OR 	
			(Of these first 3 options, the combination of FOBT or FIT every year plus flexible sigmoidoscopy every 5 years is preferable.)	
			 double-contrast barium enema every 5 years**, OR colonoscopy every 10 years 	
			*For FOBT or FIT, the take-home multiple sample method should be used.	
			**Colonoscopy should be done if the FOBT or FIT shows blood in the stool, if sigmoidoscopy results show a polyp, or if double-contrast barium enema studies show anything abnormal. If possible, polyps should be removed during the colonoscopy.	
			Prostate and Rectal (digital rectal exam (DRE) with annual physical exam (1 bonus point if student lists DRE)	